[1] Cessak G, Kuzawińska O, Burda A, et al.TNF inhibitors -Mechanisms of action, approved and off-label indications[J]. Pharmacol Rep,2014,66(5):836-844.
[2] Brinster A, Guillot X1, Prati C, et al. Anti-TNF treatment of reactive arthritis. A monocentric experience[J]. Joint Bone Spine,2016,25(5):22-24.
[3] Firinu D, Murgia G, Lorrai MM, et al.Biological treatments for SAPHO syndrome: an update[J]. Inflamm Allergy Drug Targets,2014,13(3):199-205.
[4] Matsukawa A, Yoshimura T, Maeda T, et al.Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis[J]. Lab Invest,1998,78(5):559-569.
[5] Thomas-Pohl M, Tissot A, Banal F, et al.Spectacular evolution of reactive arthritis after early treatment with infliximab[J]. Joint Bone Spine, 2012,79(5):524.
[6] 韩依轩, 邱虹, 杨文浩,等. 肿瘤坏死因子拮抗剂成功治疗难治性痛风一例报告并文献复习[J]. 天津医药, 2013,41(2):181-182.
[7] 李忱, 王景, 史小虎, 等. 35例难治性SAPHO综合征患者应用肿瘤坏死因子α拮抗剂的治疗随访[J]. 临床荟萃,2016,31(1):45-47.
[8] 杨晓珊, 王萍, 邹霓. 阿达木单抗-肿瘤坏死因子抑制剂在难治性反应性关节炎治疗中的效果评价[J]. 中国综合临床,2014,30(10):1058-1059.
[9] 李忱, 李菁, 董振华,等.抗肿瘤坏死因子-α拮抗剂在SAPHO综合征治疗中的应用[J]. 医学研究杂志,2013, 42(4):91-95.
[10] Tausche AK, Richter K, Grässler A, et al.Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option[J]. Ann Rheum Dis, 2004,63(10):1351-1352.
[11] Jarrot PA, Kaplanski G.Anti-TNF-alpha therapy and systemic vasculitis[J]. Mediators Inflamm,2014,2014:493 593.
[12] Li J, Fernando S, Herkes G.Use of infliximab and other biologics in Behçet disease[J]. Intern Med J,2014,44(1):96-100.
[13] Caso F, Costa L, Rigante D, et al.Biological treatments in Behçet's disease: beyond anti-TNF therapy[J]. Mediators Inflamm,2014,2014:107421.
[14] Melikoglu M, Fresko I, Mat C,et al.Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study[J]. J Rheumatol,2005,32(1):98-105.
[15] 陈志涵, 林禾, 高飞. 英夫利昔单抗治疗肠白塞病二例并文献复习[J]. 中国全科医学,2014,17(36):4350-4352.
[16] Comarmond C, Plaisier E, Dahan K, et al.Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature[J]. Autoimmun Rev,2012,11(9):678-684.
[17] Novikov PI, Smitienko IO, Moiseev SV.Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature[J]. Clin Rheumatol,2013 ,32(12):1827-1832.
[18] 帅宗文, 徐建华. 大血管炎的诊治进展[J]. 临床内科杂志, 2014,31(10):656-660.
[19] Mariani N, So A, Aubry-Rozier B.Two cases of Takayasu's arteritis occurring under anti-TNF therapy[J]. Joint Bone Spine, 2013,80(2):211-213.
[20] Eleftheriou D, Melo M, Marks SD, et al.Biologic therapy in primary systemic vasculitis of the young[J]. Rheumato-logy (Oxford),2009,48(8):978-986.
[21] Valor L, Monteagudo I, de la Torre I, et al. Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept[J]. Mod Rheumatol,2014,24(4):688-689.
[22] 黄灿辉, 陶怡. 结节性多动脉炎的诊治进展[J]. 临床内科杂志, 2014, 31(10):664-667.
[23] Noronha IL, Krüger C, Andrassy K, et al.In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis[J]. Kidney Int,1993,43(3):682-692.
[24] Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis[J]. N Engl J Med,2005,352(4):351-361.
[25] 邹耀红, 袁风红. 抗中性粒细胞胞质抗体相关性血管炎的生物治疗[J]. 世界临床药物,2008,29(11):674-678.
[26] Salvarani C, Macchioni P, Manzini C, et al.Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial[J]. Ann Intern Med,2007,146(9):631-639.
[27] Dejaco C, Singh YP2, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J]. Ann Rheum Dis,2015,74(10):1799-1807.
[28] Zampieri S, Alaibac M, Iaccarino L, et al.Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus[J].Ann Rheum Dis,2006,65(4):545-548.
[29] 雷贞莉. 31例系统性红斑狼疮血清TNF-α分析[J]. 现代临床医学,2003,29(6):341.
[30] 陈美良, 宁昌国. 干燥综合征患者疾病活动性与外周血肿瘤坏死因子-α相关关系的临床研究[J]. 中国药物与临床,2012,12(2):235-236.
[31] Bosello S, De Santis M, Tolusso B, et al.Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis se-condary to systemic sclerosis[J]. Ann Intern Med,2005, 143(12):918-920.
[32] Aringer M, Graninger WB, Steiner G, et al.Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study[J]. Arthritis Rheum,2004,50(10):3161-3169.
[33] Gatto M, Saccon F, Zen M, et al.Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis[J]. J Autoimmun,2016,74:94-105.
[34] Medina-Rosas J, Al-Rayes H, Moustafa AT, et al.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials[J]. Expert Opin Biol Ther,2016,16(10):1225-1238.
[35] Mariette X, Ravaud P, Steinfeld S, et al.Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)[J]. Arthritis Rheum,2004,50(4):1270-1276.
[36] Nocturne G, Cornec D2, Seror R, et al. Use of Biologics in Sjögren's Syndrome[J]. Rheum Dis Clin North Am,2016,42(3):407-417.
[37] 樊雪, 朱晨雨,孙秋宁.生物制剂治疗系统性硬化病的研究进展[J]. 国际皮肤性病学杂志,2016,42(2):1673-1674.
[38] Distler JH, Jordan S, Airo P, et al.Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique[J]. Clin Exp Rheumatol,2011,29(2 Suppl 65):S40-S45.
[39] Al-Homood IA.Biologic treatments for adult-onset Still's disease[J]. Rheumatology (Oxford),2014,53(1):32-38.
[40] 石晶, 聂振华. 成人Still病的研究进展[J]. 国际皮肤性病学杂志,2015,41(1):12-14.
[41] Maria AT, Le Quellec A2, Jorgensen C, et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions[J]. Autoimmun Rev,2014,13(11):1149-1159.
[42] Ortiz-Sanjuán F, Blanco R, Calvo-Rio V, et al.Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients[J]. Arthritis Rheumatol,2014, 66(6):1659-1665.
[43] Nishina N, Kaneko Y, Kameda H, et al.The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study[J]. Mod Rheumatol,2015,25(3):401-404. |
